Akorn (AKRX) Trading Down 11.7%

Shares of Akorn, Inc. (NASDAQ:AKRX) were down 11.7% on Wednesday . The stock traded as low as $3.47 and last traded at $3.48. Approximately 4,433,883 shares were traded during mid-day trading, an increase of 26% from the average daily volume of 3,508,031 shares. The stock had previously closed at $3.94.

Several equities analysts have commented on the stock. BidaskClub cut shares of Akorn from a “strong-buy” rating to a “buy” rating in a research note on Friday, December 7th. Zacks Investment Research downgraded shares of Akorn from a “hold” rating to a “sell” rating in a research report on Tuesday, November 27th. Piper Jaffray Companies raised shares of Akorn from a “neutral” rating to an “overweight” rating and lifted their target price for the stock from $5.00 to $9.00 in a research report on Wednesday, October 17th. Jefferies Financial Group dropped their target price on shares of Akorn to $6.00 and set a “hold” rating on the stock in a research report on Wednesday, October 3rd. Finally, Craig Hallum set a $11.00 target price on shares of Akorn and gave the stock a “buy” rating in a research report on Sunday, December 9th. Five equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average price target of $13.67.

The company has a debt-to-equity ratio of 1.26, a quick ratio of 2.46 and a current ratio of 3.47.

Akorn (NASDAQ:AKRX) last issued its quarterly earnings data on Tuesday, November 6th. The company reported ($0.10) earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.07 by ($0.17). Akorn had a negative return on equity of 14.97% and a negative net margin of 34.69%. The firm had revenue of $165.63 million during the quarter, compared to analyst estimates of $185.36 million. Research analysts anticipate that Akorn, Inc. will post -0.13 earnings per share for the current fiscal year.

In related news, EVP Joseph Bonaccorsi bought 25,000 shares of the company’s stock in a transaction that occurred on Friday, December 14th. The shares were acquired at an average price of $4.48 per share, with a total value of $112,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 3.50% of the stock is currently owned by insiders.

A number of hedge funds have recently made changes to their positions in AKRX. State of Alaska Department of Revenue bought a new stake in Akorn in the 4th quarter valued at $107,000. Tower Research Capital LLC TRC increased its holdings in Akorn by 672.9% in the 3rd quarter. Tower Research Capital LLC TRC now owns 10,280 shares of the company’s stock valued at $134,000 after buying an additional 8,950 shares during the period. Baird Financial Group Inc. acquired a new stake in shares of Akorn in the 3rd quarter valued at $135,000. Brown Advisory Inc. acquired a new stake in shares of Akorn in the 3rd quarter valued at $139,000. Finally, Quantbot Technologies LP acquired a new stake in shares of Akorn in the 3rd quarter valued at $174,000. 64.90% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: This story was originally posted by PressOracle and is the sole property of of PressOracle. If you are accessing this story on another domain, it was illegally copied and reposted in violation of U.S. and international trademark & copyright law. The correct version of this story can be read at https://pressoracle.com/news/2019/01/11/akorn-akrx-trading-down-11-7.html.

About Akorn (NASDAQ:AKRX)

Akorn, Inc, a specialty generic pharmaceutical company, develops, manufactures, and markets generic and branded prescription pharmaceuticals, over-the-counter (OTC) consumer health products, and animal health pharmaceuticals in the United States and internationally. The company operates in two segments, Prescription Pharmaceuticals and Consumer Health.

Featured Article: How to calculate the intrinsic value of a stock

Receive News & Ratings for Akorn Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akorn and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Leave a Reply